Consensus on the management of metabolic dysfunction-associated fatty liver disease among Chinese adults with HIV infection

Life expectancy of people living with HIV （PLWH） has markedly increased due to the widespread use of combination antiretroviral therapy （cART）. However， metabolic dysfunction-associated steatotic liver disease （MASLD） is a prevalent and severe comorbidity in this population. PLWH with MASLD exhibit distinct pathophysiological features， and disease management is further complicated by the long-term exposure to cART. Existing MASLD guidelines have not fully addressed the unique characteristics of PLWH. This expert consensus aims to provide standardized recommendations for the screening， diagnosis， and management of MASLD in PLWH， with an emphasis on early detection， identification of high-risk populations， individualized risk assessment， and multidisciplinary care to improve long-term outcomes and reduce the risk of liver disease progression and associated complications.